50 years I’ve been bumbling around this planet, and the best damn weekend I’ve had on it to date occurred recently, under the influence of mushrooms.
Not sure what took them so long, but there’s a new CEO at Canopy Growth Corp (WEED.T), and he’s exactly what we thought he’d be; a finance guy, and a Constellation Brands (STZ.NYSE) guy.
Dionymed (DYME.C) gives investors a checklist for disaster, and Invictus (GENE.V) is ticking a lot of boxes
Dionymed Brands (DYME.C) is – sorry, was – the low hanging fruit of the cannabis bubble burst. It was always a goner for anyone who looked hard enough, but in a market where aspiration was rewarded more than perspiration, Dionymed sent out all the right news releases to keep the joke going longer than it should.
Isracann BioSciences (IPOT) is the first pure pot play growing in the Promised Land. You may not think this middle east nation state is a tactical choice when it comes to legal weed, but Israel leads the world in medical cannabis research with some researchers joking they are going to write the Torah of cannabis.
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth a combined $5.2 billion.
The US Dollar is getting a lot of discussion in the financial media, in politics, by billionaires, and by a lot of market participants and fund managers. For good reason: it is the reserve currency.
Oracle (ORCL.NYSE) leverages artificial intelligence to connect cancer patients with clinical trials
Oracle Health Sciences, the medical sciences wing of Oracle (ORCL.NYSE), is participating in The Opportunity Project (TOP) Technology Spring: Creating the Future of Health.